Industry Events Calendar

Applications of artificial intelligence in health care are expanding rapidly. Despite its great long-term potential, risks and challenges remain for both AI developers and their partners in health care, the life sciences industry and digital health.

This Harvard Medical School Executive Education program will allow leaders across the ecosystem to gain insights into what it takes to successfully utilize AI in the unique cultural, economic and regulatory context of health care. Interactive sessions will address technical concepts as well as real-world implementation, with examples drawn from health care delivery/operations and drug development.

The curriculum will feature a combination of live virtual class sessions, small group application exercises, pre-work and vigorous discussions. Upon completion of the program, participants will be able to immediately apply insights gained to the fast-moving and complex health care sector. A certificate of completion will be provided.

Learn More

Accelerating R&D to Commercialization by Leveraging Predictive Biomarkers & Clinical Diagnostics Evidence for Best Patient Outcomes in Target Populations
The 11th World Clinical Biomarkers & CDx Summit returns in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic, their clinical validation and later commercialization with a CDx.

With over half of drugs approved by the FDA now supported by a biomarker and as new CDx collaborations are announced on an almost weekly basis, demand for diagnostic tools enabling earlier, more precise, therapeutic interventions is at an all time high. Join with 650+ key stakeholders across biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market.

Learn More

The 12th Annual World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery, translational, and manufacturing challenges faced in the bispecific field. Whatever your role and interest, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients.

Discover who the 50+ expert speakers are, and the topics they will examine, including how:

– OSE Immunotherapeutics is pioneering their unique platform BiCKI a bispecific platform optimized for the development and manufacturing of bispecific cytokine fusion proteins
– GT Biopharma and Light Chain Bioscience are showcasing the next generation of innate cell engagers for the treatment of solid tumors
– Merus, Pfizer, and Innate Pharma are expanding the boundaries of biotherapeutics with tri-specific and multi-specific antibodies
– Genentech, Pfizer, and City of Hope are discussing approaches to reduce on-target off-tumor toxicities including dosing strategies in liquid and solid tumor indications
– Xencor, Harbour Biomed, and Harpoon Therapeutics will discuss their unique platforms and CMC strategies for scale-up and production
– IGM Biosciences and MacroGenics will evaluate biomarker strategies for bispecific candidates during clinical development

Register now

European commercialization can at first sight, appear a little daunting. 30 EAA countries (European Economic Area) plus UK and Switzerland, a population of 370 million, multiple regulatory systems, different reimbursement environments and labor laws, as well as a melting pot of languages and culture. That is why this salon is a must for any CEO considering European commercialization as a strategic option.

With success the rewards of going it alone can be stellar in terms of increased access to your medicines for patients beyond the US and the potential to enhance your market cap exponentially.

The salon draws on the current experience of senior Biotech leaders, highlighting some of the key decision areas including location for the European HQ, timing, phasing and cadence of roll out and perhaps most importantly, the bear traps to avoid!

Featuring:
Sean Morgan-Jones, Chief Commercial Officer, Morgan Prestwich (Moderator)
Barry Greene, CEO, Sage Therapeutics
Stephanie Léouzon, Partner & Head of Torreya Europe
David Meeker, MD, CEO, Rhythm Pharmaceuticals
Anant Murthy, PhD, General Manager, Europe, Argenx

Learn More

In this Harvard Medical School Executive Education webinar, Annie Brewster, MD will discuss the transformational power of sharing patient voices and stories. A new diagnosis is just the starting point. The patient will then begin their journey of integrating this diagnosis into their life, into their relationships and their identity.

Brewster will discuss the power of patient stories and how they can improve health care and spur innovations that meet patient needs.

Learn More

Biosimilars were anticipated to be a solution to the soaring cost of prescription medicines to treat a slew of diseases. Have they reached their potential?

Some see encouraging signs of increased adoption rates for these treatments, which are made from living cells and nearly identical to their biologic counterparts. Others fear they are meeting resistance.

STAT’s Ed Silverman will convene a discussion on what it will take to create a functioning biosimilar market in the U.S.

Speakers:

• Madelaine A. Feldman, M.D., FACR, president, Coalition of State Rheumatology Organizations; clinical assistant professor of medicine, Tulane University School of Medicine
• Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president, biosimilars, Cardinal Health
• Gillian Woollett, principal research scientist, Avalere Health

Register now